Skip to main content
PMC home page
Environmental Health Perspectives logoLink to Environmental Health Perspectives
. 1995 Nov;103(Suppl 8):191–196. doi: 10.1289/ehp.95103s8191

Nonhormonal drugs and cancer.

P D Stolley 1, S H Zahm 1
PMCID: PMC1518949  PMID: 8741782

Abstract

Nonhormonal drugs probably account for only a small proportion of human cancer but have contributed many valuable insights into carcinogenic mechanisms. The antineoplastics, radiopharmaceuticals, and a few other agents account for most of the known drug-induced cancer. A number of other agents are under suspicion, usually due to studies in laboratory animals or to preliminary clinical or epidemiologic observations. This group includes some drugs in widespread use such as clofibrate and cimetidine. For a few drugs that are carcinogenic in animals, such as dapsone and isoniazid, epidemiologic studies have shown little to no evidence of carcinogenicity. Recent experimental studies have shown tumor promotion by the commonly used antidepressants amitriptyline and fluoxetine and some antihistamines, which deserve epidemiologic investigation of cancer risk. Some drugs may also protect against cancer, as suggested by the lower risk of colorectal cancer among regular users of nonsteroidal antiinflammatory drugs. Pharmacoepidemiologic studies must take into account possible confounding by the original conditions for which drugs were taken and the typically long latency period of drug-induced cancer. Improved postmarketing surveillance, continued routine case-control surveillance, and ad hoc case-control and cohort studies are needed to evaluate drugs already in use as well as newly introduced agents.

Full text

PDF
191

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allen R. W., Jr, Ogden B., Bentley F. L., Jung A. L. Fetal hydantoin syndrome, neuroblastoma, and hemorrhagic disease in a neonate. JAMA. 1980 Sep 26;244(13):1464–1465. [PubMed] [Google Scholar]
  2. Armstrong B., Stevens N., Doll R. Retrospective study of the association between use of rauwolfia derivatives and breast cancer in English women. Lancet. 1974 Sep 21;2(7882):672–675. doi: 10.1016/s0140-6736(74)93258-9. [DOI] [PubMed] [Google Scholar]
  3. Beard C. M., Noller K. L., O'Fallon W. M., Kurland L. T., Dockerty M. B. Lack of evidence for cancer due to use of metronidazole. N Engl J Med. 1979 Sep 6;301(10):519–522. doi: 10.1056/NEJM197909063011003. [DOI] [PubMed] [Google Scholar]
  4. Bernstein L., Ross R. K. Prior medication use and health history as risk factors for non-Hodgkin's lymphoma: preliminary results from a case-control study in Los Angeles County. Cancer Res. 1992 Oct 1;52(19 Suppl):5510s–5515s. [PubMed] [Google Scholar]
  5. Bhide S. V., Maru G. B., Sawai M. M., Ranadive K. J. Isoniazid tumorigenicity in mice under different experimental conditions. Int J Cancer. 1978 Mar 15;21(3):381–386. doi: 10.1002/ijc.2910210320. [DOI] [PubMed] [Google Scholar]
  6. Blattner W. A., Henson D. E., Young R. C., Fraumeni J. F., Jr Malignant mesenchymoma and birth defects. Prenatal exposure to phenytoin. JAMA. 1977 Jul 25;238(4):334–335. [PubMed] [Google Scholar]
  7. Boice J. D., Fraumeni J. F., Jr Late effects following isoniazid therapy. Am J Public Health. 1980 Sep;70(9):987–989. doi: 10.2105/ajph.70.9.987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Brandes L. J., Arron R. J., Bogdanovic R. P., Tong J., Zaborniak C. L., Hogg G. R., Warrington R. C., Fang W., LaBella F. S. Stimulation of malignant growth in rodents by antidepressant drugs at clinically relevant doses. Cancer Res. 1992 Jul 1;52(13):3796–3800. [PubMed] [Google Scholar]
  9. Brandes L. J., Warrington R. C., Arron R. J., Bogdanovic R. P., Fang W., Queen G. M., Stein D. A., Tong J., Zaborniak C. L., LaBella F. S. Enhanced cancer growth in mice administered daily human-equivalent doses of some H1-antihistamines: predictive in vitro correlates. J Natl Cancer Inst. 1994 May 18;86(10):770–775. doi: 10.1093/jnci/86.10.770. [DOI] [PubMed] [Google Scholar]
  10. Brinton L. A., Hoover R., Jacobson R. R., Fraumeni J. F., Jr Cancer mortality among patients with Hansen's disease. J Natl Cancer Inst. 1984 Jan;72(1):109–114. doi: 10.1093/jnci/72.1.109. [DOI] [PubMed] [Google Scholar]
  11. Buring J. E., Lee I. M., Hennekens C. H. Nonsteroidal antiinflammatory drugs and colorectal cancer. A promising hypothesis but not yet proven. Cancer. 1994 Oct 1;74(7):1837–1839. doi: 10.1002/1097-0142(19941001)74:7<1837::aid-cncr2820740702>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  12. Campbell A. H., Guilfoyle P. Pulmonary tuberculosis, isoniazid and cancer. Br J Dis Chest. 1970 Jul;64(3):141–149. doi: 10.1016/s0007-0971(70)80002-x. [DOI] [PubMed] [Google Scholar]
  13. Costello H. D., Snider D. E., Jr The incidence of cancer among participants in controlled, randomized isoniazid preventive therapy trial. Am J Epidemiol. 1980 Jan;111(1):67–74. doi: 10.1093/oxfordjournals.aje.a112875. [DOI] [PubMed] [Google Scholar]
  14. Craven P. A., Saito R., DeRubertis F. R. Role of local prostaglandin synthesis in the modulation of proliferative activity of rat colonic epithelium. J Clin Invest. 1983 Oct;72(4):1365–1375. doi: 10.1172/JCI111093. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Danielson D. A., Jick H., Hunter J. R., Stergachis A., Madsen S. Nonestrogenic drugs and breast cancer. Am J Epidemiol. 1982 Aug;116(2):329–332. doi: 10.1093/oxfordjournals.aje.a113416. [DOI] [PubMed] [Google Scholar]
  16. Earnest D. L., Hixson L. J., Alberts D. S. Piroxicam and other cyclooxygenase inhibitors: potential for cancer chemoprevention. J Cell Biochem Suppl. 1992;16I:156–166. doi: 10.1002/jcb.240501330. [DOI] [PubMed] [Google Scholar]
  17. Finkle W. D., McLaughlin J. K., Rasgon S. A., Yeoh H. H., Low J. E. Increased risk of renal cell cancer among women using diuretics in the United States. Cancer Causes Control. 1993 Nov;4(6):555–558. doi: 10.1007/BF00052431. [DOI] [PubMed] [Google Scholar]
  18. Fraumeni J. F., Jr Bone marrow depression induced by chloramphenicol or phenylbutazone. Leukemia and other sequelae. JAMA. 1967 Sep 11;201(11):828–834. [PubMed] [Google Scholar]
  19. Friedman G. D. Cancer after metronidazole. N Engl J Med. 1980 Feb 28;302(9):519–519. doi: 10.1056/NEJM198002283020911. [DOI] [PubMed] [Google Scholar]
  20. Friedman G. D., Ury H. K. Initial screening for carcinogenicity of commonly used drugs. J Natl Cancer Inst. 1980 Oct;65(4):723–733. doi: 10.1093/jnci/65.4.723. [DOI] [PubMed] [Google Scholar]
  21. Gann P. H., Manson J. E., Glynn R. J., Buring J. E., Hennekens C. H. Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst. 1993 Aug 4;85(15):1220–1224. doi: 10.1093/jnci/85.15.1220. [DOI] [PubMed] [Google Scholar]
  22. Giardiello F. M., Hamilton S. R., Krush A. J., Piantadosi S., Hylind L. M., Celano P., Booker S. V., Robinson C. R., Offerhaus G. J. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med. 1993 May 6;328(18):1313–1316. doi: 10.1056/NEJM199305063281805. [DOI] [PubMed] [Google Scholar]
  23. Glassroth J. L., Snider D. E., Comstock G. W. Urinary tract cancer and isoniazid. Am Rev Respir Dis. 1977 Aug;116(2):331–333. doi: 10.1164/arrd.1977.116.2.331. [DOI] [PubMed] [Google Scholar]
  24. Griciute L., Tomatis L. Carcinogenicity of dapsone of mice and rats. Int J Cancer. 1980 Jan 15;25(1):123–129. doi: 10.1002/ijc.2910250116. [DOI] [PubMed] [Google Scholar]
  25. Gridley G., McLaughlin J. K., Ekbom A., Klareskog L., Adami H. O., Hacker D. G., Hoover R., Fraumeni J. F., Jr Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst. 1993 Feb 17;85(4):307–311. doi: 10.1093/jnci/85.4.307. [DOI] [PubMed] [Google Scholar]
  26. HEIN J., STEFANI H. Die gewebliche Reaktion der Lungentuberkulose bei Isonikotinsäurehydrazid-Behandlung. Z Tuberk. 1952;101(3-4):180–187. [PubMed] [Google Scholar]
  27. Hammond E. C., Selikoff I. J., Robitzek E. H. Isoniazid therapy in relation to later occurrence of cancer in adults and in infants. Br Med J. 1967 Jun 24;2(5555):792–795. doi: 10.1136/bmj.2.5555.792. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Heath C. W., Jr, Thun M. J., Greenberg E. R., Levin B., Marnett L. J. Nonsteroidal antiinflammatory drugs and human cancer. Report of an interdisciplinary research workshop. Cancer. 1994 Nov 15;74(10):2885–2888. doi: 10.1002/1097-0142(19941115)74:10<2885::aid-cncr2820741023>3.0.co;2-p. [DOI] [PubMed] [Google Scholar]
  29. Hiatt R. A., Tolan K., Quesenberry C. P., Jr Renal cell carcinoma and thiazide use: a historical, case-control study (California, USA). Cancer Causes Control. 1994 Jul;5(4):319–325. doi: 10.1007/BF01804982. [DOI] [PubMed] [Google Scholar]
  30. Hixson L. J., Alberts D. S., Krutzsch M., Einsphar J., Brendel K., Gross P. H., Paranka N. S., Baier M., Emerson S., Pamukcu R. Antiproliferative effect of nonsteroidal antiinflammatory drugs against human colon cancer cells. Cancer Epidemiol Biomarkers Prev. 1994 Jul-Aug;3(5):433–438. [PubMed] [Google Scholar]
  31. Iishi H., Tatsuta M., Baba M., Taniguchi H. Enhancement by the tricyclic antidepressant, desipramine, of experimental carcinogenesis in rat colon induced by azoxymethane. Carcinogenesis. 1993 Sep;14(9):1837–1840. doi: 10.1093/carcin/14.9.1837. [DOI] [PubMed] [Google Scholar]
  32. Jekel J. F., Freeman D. H., Meigs J. W. A study of trends in upper arm soft tissue sarcomas in the state of Connecticut following the introduction of alum-absorbed allergenic extract. Ann Allergy. 1978 Jan;40(1):28–31. [PubMed] [Google Scholar]
  33. Kantor A. F., Hartge P., Hoover R. N., Fraumeni J. F., Jr Tuberculosis chemotherapy and risk of bladder cancer. Int J Epidemiol. 1985 Mar;14(1):182–184. doi: 10.1093/ije/14.1.182. [DOI] [PubMed] [Google Scholar]
  34. Karmali R. A., Volkman A., Muse P., Louis T. M. The influence of diazepam administration in rats bearing the R3230AC mammary carcinoma. Prostaglandins Med. 1979 Sep;3(3):193–198. doi: 10.1016/0161-4630(79)90103-4. [DOI] [PubMed] [Google Scholar]
  35. Kaufman D. W., Shapiro S., Slone D., Rosenberg L., Helmrich S. P., Miettinen O. S., Stolley P. D., Levy M., Schottenfeld D. Diazepam and the risk of breast cancer. Lancet. 1982 Mar 6;1(8271):537–539. doi: 10.1016/s0140-6736(82)92046-3. [DOI] [PubMed] [Google Scholar]
  36. Kleinerman R. A., Brinton L. A., Hoover R., Fraumeni J. F., Jr Diazepam use and progression of breast cancer. Cancer Res. 1984 Mar;44(3):1223–1225. [PubMed] [Google Scholar]
  37. Kleinerman R. A., Rinton L. A., Hoover R., Fraumeni J. F., Jr Diazepam and breast cancer. Lancet. 1981 May 23;1(8230):1153–1153. doi: 10.1016/s0140-6736(81)92314-x. [DOI] [PubMed] [Google Scholar]
  38. Kolonel L. N., Hirohata T. Leprosy and cancer: a retrospective cohort study in Hawaii. J Natl Cancer Inst. 1977 Jun;58(6):1577–1581. doi: 10.1093/jnci/58.6.1577. [DOI] [PubMed] [Google Scholar]
  39. Kreiger N., Marrett L. D., Dodds L., Hilditch S., Darlington G. A. Risk factors for renal cell carcinoma: results of a population-based case-control study. Cancer Causes Control. 1993 Mar;4(2):101–110. doi: 10.1007/BF00053150. [DOI] [PubMed] [Google Scholar]
  40. Kudo T., Narisawa T., Abo S. Antitumor activity of indomethacin on methylazoxymethanol-induced large bowel tumors in rats. Gan. 1980 Apr;71(2):260–264. [PubMed] [Google Scholar]
  41. Labayle D., Fischer D., Vielh P., Drouhin F., Pariente A., Bories C., Duhamel O., Trousset M., Attali P. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology. 1991 Sep;101(3):635–639. doi: 10.1016/0016-5085(91)90519-q. [DOI] [PubMed] [Google Scholar]
  42. Legator M. S., Connor T. H., Stoeckel M. Detection of mutagenic activity of metronidazole and niridazole in body fluids of humans and mice. Science. 1975 Jun 13;188(4193):1118–1119. doi: 10.1126/science.766186. [DOI] [PubMed] [Google Scholar]
  43. Li F. P., Willard D. R., Goodman R., Vawter G. Malignant lymphoma after diphenylhydantoin (dilantin) therapy. Cancer. 1975 Oct;36(4):1359–1362. doi: 10.1002/1097-0142(197510)36:4<1359::aid-cncr2820360426>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  44. Lindblad P., Zack M., Adami H. O., Ericson A. Maternal and perinatal risk factors for Wilms' tumor: a nationwide nested case-control study in Sweden. Int J Cancer. 1992 Apr 22;51(1):38–41. doi: 10.1002/ijc.2910510108. [DOI] [PubMed] [Google Scholar]
  45. Logan R. F., Little J., Hawtin P. G., Hardcastle J. D. Effect of aspirin and non-steroidal anti-inflammatory drugs on colorectal adenomas: case-control study of subjects participating in the Nottingham faecal occult blood screening programme. BMJ. 1993 Jul 31;307(6899):285–289. doi: 10.1136/bmj.307.6899.285. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Lupulescu A. Enhancement of carcinogenesis by prostaglandins. Nature. 1978 Apr 13;272(5654):634–636. doi: 10.1038/272634a0. [DOI] [PubMed] [Google Scholar]
  47. MINKOWITZ S. MULTIPLE CARCINOMATA FOLLOWING INGESTION OF MEDICINAL ARSENIC. Ann Intern Med. 1964 Aug;61:296–299. doi: 10.7326/0003-4819-61-2-296. [DOI] [PubMed] [Google Scholar]
  48. Marnett L. J. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res. 1992 Oct 15;52(20):5575–5589. [PubMed] [Google Scholar]
  49. McCredie M., Stewart J. H., Day N. E. Different roles for phenacetin and paracetamol in cancer of the kidney and renal pelvis. Int J Cancer. 1993 Jan 21;53(2):245–249. doi: 10.1002/ijc.2910530212. [DOI] [PubMed] [Google Scholar]
  50. McCredie M., Stewart J. H., Ford J. M. Analgesics and tobacco as risk factors for cancer of the ureter and renal pelvis. J Urol. 1983 Jul;130(1):28–30. doi: 10.1016/s0022-5347(17)50936-2. [DOI] [PubMed] [Google Scholar]
  51. McCredie M., Stewart J. H., Ford J. M., MacLennan R. A. Phenacetin-containing analgesics and cancer of the bladder or renal pelvis in women. Br J Urol. 1983 Apr;55(2):220–224. doi: 10.1111/j.1464-410x.1983.tb06561.x. [DOI] [PubMed] [Google Scholar]
  52. McCredie M., Stewart J. H. Risk factors for kidney cancer in New South Wales, Australia. II. Urologic disease, hypertension, obesity, and hormonal factors. Cancer Causes Control. 1992 Jul;3(4):323–331. doi: 10.1007/BF00146885. [DOI] [PubMed] [Google Scholar]
  53. McIllmurray M. B., Langman M. J. Soft tissue sarcomas and intramuscular injections: an epidemiological survey. Br Med J. 1978 Sep 23;2(6141):864–865. doi: 10.1136/bmj.2.6141.864-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. McLaughlin J. K., Blot W. J., Fraumeni J. F., Jr Diuretics and renal cell cancer. J Natl Cancer Inst. 1988 May 4;80(5):378–378. doi: 10.1093/jnci/80.5.378. [DOI] [PubMed] [Google Scholar]
  55. McLaughlin J. K., Mandel J. S., Blot W. J., Schuman L. M., Mehl E. S., Fraumeni J. F., Jr A population--based case--control study of renal cell carcinoma. J Natl Cancer Inst. 1984 Feb;72(2):275–284. [PubMed] [Google Scholar]
  56. Mellemgaard A., Møller H., Olsen J. H. Diuretics may increase risk of renal cell carcinoma. Cancer Causes Control. 1992 Jul;3(4):309–312. doi: 10.1007/BF00146883. [DOI] [PubMed] [Google Scholar]
  57. Miller C. T. Letter: Isoniazid and cancer risks. JAMA. 1974 Dec 2;230(9):1254–1254. doi: 10.1001/jama.1974.03240090014005. [DOI] [PubMed] [Google Scholar]
  58. Miller C. T., Neutel C. I., Nair R. C., Marrett L. D., Last J. M., Collins W. E. Relative importance of risk factors in bladder carcinogenesis. J Chronic Dis. 1978 Jan;31(1):51–56. doi: 10.1016/0021-9681(78)90080-2. [DOI] [PubMed] [Google Scholar]
  59. Muscat J. E., Stellman S. D., Wynder E. L. Nonsteroidal antiinflammatory drugs and colorectal cancer. Cancer. 1994 Oct 1;74(7):1847–1854. doi: 10.1002/1097-0142(19941001)74:7<1847::aid-cncr2820740704>3.0.co;2-#. [DOI] [PubMed] [Google Scholar]
  60. Møller H., Lindvig K., Klefter R., Mosbech J., Møller Jensen O. Cancer occurrence in a cohort of patients treated with cimetidine. Gut. 1989 Nov;30(11):1558–1562. doi: 10.1136/gut.30.11.1558. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Møller H., Mellemgaard A. Prostate cancer incidence in cimetidine users. J Natl Cancer Inst. 1992 Mar 4;84(5):359–360. doi: 10.1093/jnci/84.5.359. [DOI] [PubMed] [Google Scholar]
  62. Oleinick A. Survival among leprosy patients with special consideration of cancer as a cause of death. Int J Lepr Other Mycobact Dis. 1968 Jul-Sep;36(3):318–327. [PubMed] [Google Scholar]
  63. Olsen J. H., Boice J. D., Jr, Jensen J. P., Fraumeni J. F., Jr Cancer among epileptic patients exposed to anticonvulsant drugs. J Natl Cancer Inst. 1989 May 10;81(10):803–808. doi: 10.1093/jnci/81.10.803. [DOI] [PubMed] [Google Scholar]
  64. Paganini-Hill A., Chao A., Ross R. K., Henderson B. E. Aspirin use and chronic diseases: a cohort study of the elderly. BMJ. 1989 Nov 18;299(6710):1247–1250. doi: 10.1136/bmj.299.6710.1247. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Paganini-Hill A., Hsu G., Ross R. K., Henderson B. E. Aspirin use and incidence of large-bowel cancer in a California retirement community. J Natl Cancer Inst. 1991 Aug 21;83(16):1182–1183. doi: 10.1093/jnci/83.16.1182-a. [DOI] [PubMed] [Google Scholar]
  66. Peleg I. I., Maibach H. T., Brown S. H., Wilcox C. M. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch Intern Med. 1994 Feb 28;154(4):394–399. [PubMed] [Google Scholar]
  67. Pendergrass T. W. Letter: Fetal hydantoin syndrome and neuroblastoma. Lancet. 1976 Jul 17;2(7977):150–150. doi: 10.1016/s0140-6736(76)92882-8. [DOI] [PubMed] [Google Scholar]
  68. Peters J. H. Carcinogenic activity of dapsone. Int J Lepr Other Mycobact Dis. 1976 Jul-Sep;44(3):383–384. [PubMed] [Google Scholar]
  69. Piper J. M., Matanoski G. M., Tonascia J. Bladder cancer in young women. Am J Epidemiol. 1986 Jun;123(6):1033–1042. doi: 10.1093/oxfordjournals.aje.a114331. [DOI] [PubMed] [Google Scholar]
  70. Piper J. M., Tonascia J., Matanoski G. M. Heavy phenacetin use and bladder cancer in women aged 20 to 49 years. N Engl J Med. 1985 Aug 1;313(5):292–295. doi: 10.1056/NEJM198508013130504. [DOI] [PubMed] [Google Scholar]
  71. Plescia O. J., Smith A. H., Grinwich K. Subversion of immune system by tumor cells and role of prostaglandins. Proc Natl Acad Sci U S A. 1975 May;72(5):1848–1851. doi: 10.1073/pnas.72.5.1848. [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Pollard M., Luckert P. H. Effect of indomethacin on intestinal tumors induced in rats by the acetate derivative of dimethylnitrosamine. Science. 1981 Oct 30;214(4520):558–559. doi: 10.1126/science.7291992. [DOI] [PubMed] [Google Scholar]
  73. Reddy B. S., Rao C. V., Rivenson A., Kelloff G. Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis. 1993 Aug;14(8):1493–1497. doi: 10.1093/carcin/14.8.1493. [DOI] [PubMed] [Google Scholar]
  74. Rigau J., Piqué J. M., Rubio E., Planas R., Tarrech J. M., Bordas J. M. Effects of long-term sulindac therapy on colonic polyposis. Ann Intern Med. 1991 Dec 15;115(12):952–954. doi: 10.7326/0003-4819-115-12-952. [DOI] [PubMed] [Google Scholar]
  75. Rosenberg L., Palmer J. R., Zauber A. G., Warshauer M. E., Stolley P. D., Shapiro S. A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst. 1991 Mar 6;83(5):355–358. doi: 10.1093/jnci/83.5.355. [DOI] [PubMed] [Google Scholar]
  76. Rosenkranz H. S., Speck W. T. Mutagenicity of metronidazole: activation by mammalian liver microsomes. Biochem Biophys Res Commun. 1975 Sep 16;66(2):520–525. doi: 10.1016/0006-291x(75)90541-0. [DOI] [PubMed] [Google Scholar]
  77. Rustia M., Shubik P. Induction of lung tumors and malignant lymphomas in mice by metronidazole. J Natl Cancer Inst. 1972 Mar;48(3):721–729. [PubMed] [Google Scholar]
  78. Sherman S., Roizen N. Fetal hydantoin syndrome and neuroblastoma. Lancet. 1976 Sep 4;1(7984):517–517. doi: 10.1016/s0140-6736(76)90808-4. [DOI] [PubMed] [Google Scholar]
  79. Shu X. O., Gao Y. T., Brinton L. A., Linet M. S., Tu J. T., Zheng W., Fraumeni J. F., Jr A population-based case-control study of childhood leukemia in Shanghai. Cancer. 1988 Aug 1;62(3):635–644. doi: 10.1002/1097-0142(19880801)62:3<635::aid-cncr2820620332>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  80. Stern R. S., Thibodeau L. A., Kleinerman R. A., Parrish J. A., Fitzpatrick T. B. Risk of cutaneous carcinoma in patients treated with oral methoxsalen photochemotherapy for psoriasis. N Engl J Med. 1979 Apr 12;300(15):809–813. doi: 10.1056/NEJM197904123001501. [DOI] [PubMed] [Google Scholar]
  81. Stolinsky D. C. Prostate cancer and histamine2 antagonists. J Natl Cancer Inst. 1991 Nov 6;83(21):1589–1589. doi: 10.1093/jnci/83.21.1589. [DOI] [PubMed] [Google Scholar]
  82. Stott H., Peto J., Stephens R., Fox W. An assessment of the carcinogenicity of isoniazid in patients with pulmonary tuberculosis. Tubercle. 1976 Mar;57(1):1–15. doi: 10.1016/0041-3879(76)90014-3. [DOI] [PubMed] [Google Scholar]
  83. THIEDE T., CHIEVITZ E., CHRISTENSEN B. C. CHLORNAPHAZINE AS A BLADDER CARCINOGEN. Acta Med Scand. 1964 Jun;175:721–725. doi: 10.1111/j.0954-6820.1964.tb00628.x. [DOI] [PubMed] [Google Scholar]
  84. Thiede T., Christensen B. C. Bladder tumours induced by chlornaphazine. A five-year follow-up study of chlornaphazine-treated patients with polycythaemia. Acta Med Scand. 1969 Jan-Feb;185(1-2):133–137. [PubMed] [Google Scholar]
  85. Thun M. J., Calle E. E., Namboodiri M. M., Flanders W. D., Coates R. J., Byers T., Boffetta P., Garfinkel L., Heath C. W., Jr Risk factors for fatal colon cancer in a large prospective study. J Natl Cancer Inst. 1992 Oct 7;84(19):1491–1500. doi: 10.1093/jnci/84.19.1491. [DOI] [PubMed] [Google Scholar]
  86. Thun M. J., Namboodiri M. M., Calle E. E., Flanders W. D., Heath C. W., Jr Aspirin use and risk of fatal cancer. Cancer Res. 1993 Mar 15;53(6):1322–1327. [PubMed] [Google Scholar]
  87. Thun M. J., Namboodiri M. M., Heath C. W., Jr Aspirin use and reduced risk of fatal colon cancer. N Engl J Med. 1991 Dec 5;325(23):1593–1596. doi: 10.1056/NEJM199112053252301. [DOI] [PubMed] [Google Scholar]
  88. Tokudome S., Kono S., Ikeda M., Kuratsune M., Kumamaru S. Cancer and other causes of death among leprosy patients. J Natl Cancer Inst. 1981 Aug;67(2):285–289. [PubMed] [Google Scholar]
  89. Travis L. B., Curtis R. E., Stovall M., Holowaty E. J., van Leeuwen F. E., Glimelius B., Lynch C. F., Hagenbeek A., Li C. Y., Banks P. M. Risk of leukemia following treatment for non-Hodgkin's lymphoma. J Natl Cancer Inst. 1994 Oct 5;86(19):1450–1457. doi: 10.1093/jnci/86.19.1450. [DOI] [PubMed] [Google Scholar]
  90. W.H.O. cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. Report of the Committee of Principal Investigators. Lancet. 1980 Aug 23;2(8191):379–385. [PubMed] [Google Scholar]
  91. Waddell W. R., Ganser G. F., Cerise E. J., Loughry R. W. Sulindac for polyposis of the colon. Am J Surg. 1989 Jan;157(1):175–179. doi: 10.1016/0002-9610(89)90442-x. [DOI] [PubMed] [Google Scholar]
  92. Waddell W. R., Loughry R. W. Sulindac for polyposis of the colon. J Surg Oncol. 1983 Sep;24(1):83–87. doi: 10.1002/jso.2930240119. [DOI] [PubMed] [Google Scholar]
  93. Wallace R. B., Sherman B. M., Bean J. A. A case-control study of breast cancer and psychotropic drug use. Oncology. 1982;39(5):279–283. doi: 10.1159/000225651. [DOI] [PubMed] [Google Scholar]
  94. Weinbren K., Salm R., Greenberg G. Intramuscular injections of iron compounds and oncogenesis in man. Br Med J. 1978 Mar 18;1(6114):683–685. doi: 10.1136/bmj.1.6114.683. [DOI] [PMC free article] [PubMed] [Google Scholar]
  95. Weinmann S., Glass A. G., Weiss N. S., Psaty B. M., Siscovick D. S., White E. Use of diuretics and other antihypertensive medications in relation to the risk of renal cell cancer. Am J Epidemiol. 1994 Nov 1;140(9):792–804. doi: 10.1093/oxfordjournals.aje.a117328. [DOI] [PubMed] [Google Scholar]
  96. Yu M. C., Mack T. M., Hanisch R., Cicioni C., Henderson B. E. Cigarette smoking, obesity, diuretic use, and coffee consumption as risk factors for renal cell carcinoma. J Natl Cancer Inst. 1986 Aug;77(2):351–356. [PubMed] [Google Scholar]
  97. Zahm S. H., Blair A., Holmes F. F., Boysen C. D., Robel R. J., Fraumeni J. F., Jr A case-control study of soft-tissue sarcoma. Am J Epidemiol. 1989 Oct;130(4):665–674. doi: 10.1093/oxfordjournals.aje.a115388. [DOI] [PubMed] [Google Scholar]

Articles from Environmental Health Perspectives are provided here courtesy of National Institute of Environmental Health Sciences

RESOURCES